Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 13 | 2025 | 572 | 3.170 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 139 | 1.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1187 | 0.990 |
Why?
|
| Stomatitis | 1 | 2024 | 17 | 0.880 |
Why?
|
| Low-Level Light Therapy | 1 | 2024 | 19 | 0.860 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2020 | 63 | 0.760 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2022 | 17 | 0.760 |
Why?
|
| Cross Infection | 2 | 2022 | 344 | 0.750 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 71 | 0.740 |
Why?
|
| Interleukin-10 | 1 | 2022 | 191 | 0.700 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 17 | 0.700 |
Why?
|
| Sepsis | 2 | 2022 | 519 | 0.690 |
Why?
|
| Sodium Benzoate | 1 | 2020 | 4 | 0.690 |
Why?
|
| Burkitt Lymphoma | 1 | 2022 | 141 | 0.680 |
Why?
|
| STAT3 Transcription Factor | 3 | 2021 | 231 | 0.670 |
Why?
|
| Hyperammonemia | 1 | 2020 | 62 | 0.660 |
Why?
|
| Atovaquone | 1 | 2019 | 10 | 0.650 |
Why?
|
| Phenylbutyrates | 1 | 2020 | 58 | 0.650 |
Why?
|
| Immunotherapy | 2 | 2025 | 750 | 0.630 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 127 | 0.620 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 131 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 236 | 0.600 |
Why?
|
| Quality Improvement | 1 | 2024 | 700 | 0.580 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 589 | 0.550 |
Why?
|
| Brain Diseases | 1 | 2020 | 310 | 0.540 |
Why?
|
| Child | 16 | 2025 | 25917 | 0.480 |
Why?
|
| Signal Transduction | 2 | 2019 | 4936 | 0.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 820 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1066 | 0.450 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2020 | 19 | 0.320 |
Why?
|
| Recurrence | 4 | 2025 | 1470 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 701 | 0.300 |
Why?
|
| Prognosis | 3 | 2024 | 5084 | 0.290 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2025 | 96 | 0.280 |
Why?
|
| Neoplasms | 1 | 2022 | 3035 | 0.270 |
Why?
|
| Humans | 25 | 2025 | 134196 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1357 | 0.260 |
Why?
|
| Child, Preschool | 8 | 2025 | 14897 | 0.240 |
Why?
|
| Oral Health | 1 | 2024 | 27 | 0.220 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2025 | 75 | 0.220 |
Why?
|
| Infant | 6 | 2025 | 13262 | 0.220 |
Why?
|
| Adolescent | 9 | 2025 | 20646 | 0.220 |
Why?
|
| Hamstring Tendons | 1 | 2023 | 1 | 0.220 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 1 | 2023 | 6 | 0.210 |
Why?
|
| Autografts | 1 | 2023 | 29 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2025 | 176 | 0.210 |
Why?
|
| Muscle Strength | 1 | 2023 | 87 | 0.200 |
Why?
|
| Haploidy | 1 | 2022 | 21 | 0.190 |
Why?
|
| Chlorhexidine | 1 | 2022 | 49 | 0.190 |
Why?
|
| Transplantation Conditioning | 1 | 2024 | 299 | 0.190 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 14 | 0.190 |
Why?
|
| CREB-Binding Protein | 1 | 2022 | 66 | 0.190 |
Why?
|
| Fractures, Spontaneous | 1 | 2021 | 18 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 106 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 214 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3800 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 625 | 0.180 |
Why?
|
| Female | 11 | 2025 | 72037 | 0.180 |
Why?
|
| STAT5 Transcription Factor | 1 | 2021 | 89 | 0.170 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 43 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2022 | 450 | 0.160 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2019 | 35 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5465 | 0.160 |
Why?
|
| Interleukin-15 | 1 | 2020 | 96 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 97 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 324 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 135 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2025 | 289 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 620 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 179 | 0.160 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 628 | 0.150 |
Why?
|
| Osteomyelitis | 1 | 2021 | 214 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 490 | 0.150 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 510 | 0.140 |
Why?
|
| Paresis | 1 | 2018 | 33 | 0.140 |
Why?
|
| Bacteremia | 1 | 2022 | 428 | 0.140 |
Why?
|
| Cell Survival | 1 | 2019 | 890 | 0.130 |
Why?
|
| Male | 10 | 2025 | 66197 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 1013 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 146 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 198 | 0.130 |
Why?
|
| Cytokines | 1 | 2022 | 1397 | 0.120 |
Why?
|
| Rhodium | 1 | 2015 | 4 | 0.120 |
Why?
|
| Young Adult | 4 | 2025 | 9961 | 0.120 |
Why?
|
| Methotrexate | 1 | 2018 | 355 | 0.120 |
Why?
|
| Genotype | 1 | 2022 | 2822 | 0.120 |
Why?
|
| Naphthalenes | 1 | 2015 | 37 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1316 | 0.120 |
Why?
|
| Hemophilia B | 1 | 2015 | 8 | 0.120 |
Why?
|
| Apoptosis | 2 | 2019 | 1945 | 0.120 |
Why?
|
| Survival Rate | 1 | 2020 | 2213 | 0.120 |
Why?
|
| Adult | 4 | 2025 | 31948 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 1135 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 447 | 0.110 |
Why?
|
| Vidarabine | 2 | 2025 | 80 | 0.110 |
Why?
|
| Cytarabine | 2 | 2025 | 102 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 898 | 0.100 |
Why?
|
| Mutation | 3 | 2022 | 6350 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4802 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1721 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2019 | 4012 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 392 | 0.090 |
Why?
|
| Mice | 4 | 2025 | 19045 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1854 | 0.080 |
Why?
|
| Animals | 4 | 2025 | 36521 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2015 | 1122 | 0.060 |
Why?
|
| Idarubicin | 1 | 2025 | 8 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2025 | 43 | 0.060 |
Why?
|
| IMP Dehydrogenase | 1 | 2025 | 27 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2025 | 344 | 0.060 |
Why?
|
| Quadriceps Muscle | 1 | 2023 | 17 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2025 | 371 | 0.050 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2023 | 29 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2023 | 286 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2025 | 352 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 40 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2022 | 48 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2021 | 56 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 87 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 628 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 69 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2021 | 100 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2021 | 76 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 128 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 82 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 318 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 343 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 504 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 177 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 914 | 0.040 |
Why?
|
| Antidotes | 1 | 2018 | 14 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 424 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 54 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 1492 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1486 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2019 | 188 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 154 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 700 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 830 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 681 | 0.030 |
Why?
|
| Factor IX | 1 | 2015 | 15 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 111 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 139 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2025 | 2735 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 223 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17579 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 610 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 223 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 362 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1922 | 0.030 |
Why?
|
| Binding Sites | 1 | 2015 | 1386 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1735 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 2588 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1835 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2562 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1876 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 21805 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 3226 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 29414 | 0.010 |
Why?
|